Drug General Information |
Drug ID |
D05SBO
|
Former ID |
DNCL002707
|
Drug Name |
LY2835219
|
Drug Type |
Small molecular drug
|
Indication |
Cancer [ICD9: 140-229; ICD10:C00-C96]
|
Phase 3 |
[1],
[2]
|
Company |
Eli Lilly
|
Structure |
|
Download
2D MOL
|
Formula |
C27H32F2N8
|
InChI |
InChI=1S/C27H32F2N8/c1-5-35-8-10-36(11-9-35)16-19-6-7-24(30-14-19)33-27-31-15-22(29)25(34-27)20-12-21(28)26-23(13-20)37(17(2)3)18(4)32-26/h6-7,12-15,17H,5,8-11,16H2,1-4H3,(H,30,31,33,34)
|
InChIKey |
UZWDCWONPYILKI-UHFFFAOYSA-N
|
PubChem Compound ID |
|
PubChem Substance ID |
96075034, 120483888, 140885353, 141321259, 163621010, 163686341, 172917432, 178103954, 185975428, 198954176, 207011353, 223404298, 223405968, 224401848, 228594084, 242651810, 248540783, 249814531, 251910681, 252215739, 252479469
|
Target and Pathway |
Target(s) |
Cell division protein kinase 4 |
Target Info |
Modulator |
[3]
|
Cell division protein kinase 6 |
Target Info |
Modulator |
[3]
|
KEGG Pathway
|
Cell cycle
|
p53 signaling pathway
|
PI3K-Akt signaling pathway
|
Tight junction
|
T cell receptor signaling pathway
|
Hepatitis B
|
Measles
|
HTLV-I infection
|
Pathways in cancer
|
Viral carcinogenesis
|
Pancreatic cancer
|
Glioma
|
Melanoma
|
Bladder cancer
|
Chronic myeloid leukemia
|
Small cell lung cancer
|
Non-small cell lung cancerhsa04110:Cell cycle
|
MicroRNAs in cancer
|
Non-small cell lung cancer
|
NetPath Pathway
|
TCR Signaling Pathway
|
EGFR1 Signaling Pathway
|
RANKL Signaling PathwayNetPath_7:TGF_beta_Receptor Signaling Pathway
|
Pathway Interaction Database
|
Regulation of nuclear SMAD2/3 signaling
|
Calcineurin-regulated NFAT-dependent transcription in lymphocytes
|
Validated targets of C-MYC transcriptional activation
|
ATF-2 transcription factor network
|
FOXM1 transcription factor network
|
Regulation of retinoblastoma proteinp73pathway:p73 transcription factor network
|
Coregulation of Androgen receptor activity
|
C-MYB transcription factor network
|
IL2 signaling events mediated by STAT5
|
Regulation of retinoblastoma protein
|
Reactome
|
Oxidative Stress Induced Senescence
|
Senescence-Associated Secretory Phenotype (SASP)
|
Oncogene Induced Senescence
|
RMTs methylate histone arginines
|
Transcriptional regulation of white adipocyte differentiation
|
Ubiquitin-dependent degradation of Cyclin D1
|
Cyclin D associated events in G1
|
Meiotic recombinationR-HSA-2559580:Oxidative Stress Induced Senescence
|
WikiPathways
|
DNA Damage Response
|
G1 to S cell cycle control
|
Ovarian Infertility Genes
|
PPAR Alpha Pathway
|
Bladder Cancer
|
S Phase
|
Transcriptional Regulation of White Adipocyte Differentiation
|
Meiotic Recombination
|
Retinoblastoma (RB) in Cancer
|
Spinal Cord Injury
|
Integrated Pancreatic Cancer Pathway
|
Prostate Cancer
|
Signaling Pathways in Glioblastoma
|
TSH signaling pathway
|
Integrated Breast Cancer Pathway
|
Integrated Cancer pathway
|
Mitotic G1-G1/S phases
|
Cell Cycle
|
miRNA Regulation of DNA Damage ResponseWP707:DNA Damage Response
|
Wnt Signaling Pathway Netpath
|
Metastatic brain tumor
|
miR-targeted genes in muscle cell - TarBase
|
miR-targeted genes in lymphocytes - TarBase
|
miR-targeted genes in leukocytes - TarBase
|
miR-targeted genes in epithelium - TarBase
|
miRNAs involved in DNA damage response
|
miRNA Regulation of DNA Damage Response
|
References |
REF 1 | ClinicalTrials.gov (NCT02152631) A Study of Abemaciclib (LY2835219) in Participants With Previously Treated Lung Cancer. U.S. National Institutes of Health. |
---|
REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7382). |
---|
REF 3 | Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. |